IDXX vs NEOG vs BFLY Stock Comparison

Idexx Laboratories, Neogen and Butterfly Network Prices as of Oct 28, 2026 Peers: Industry group
NEOG Neogen Corp
$12.12 -11.7% 1M +96.8% 1Y
Market cap
$2.68B
P/E
–
Revenue (TTM)
$883.99M
Div. yield
–
Diagnostic Equipment Healthcare
BFLY Butterfly Network, Inc.
$7.82 -14.5% 1M +253.8% 1Y
Market cap
$1.94B
P/E
–
Revenue (TTM)
$112.15M
Div. yield
–
Diagnostic Equipment Healthcare
2 wins

Head to Head

10 decided of 12

Idexx Laboratories leads on 8 of the 12 questions below (Idexx Laboratories 8, Butterfly Network 2). Which ones matter depends on what you are buying for; a cheap multiple and slow growth often come together.

QuestionIDXXNEOGBFLYLeader
Larger companyMarket capitalisation $45.40B $2.68B $1.94B IDXX
Cheaper on earningsLower P/E, profitable companies only 39.8x -47.7x -26.0x –
Cheaper on forward earningsLower price / next fiscal year consensus EPS 36.0x 37.9x — IDXX
Faster revenue growthRevenue growth, trailing twelve months +12.8% -0.3% +28.1% BFLY
More profitableNet margin, trailing twelve months 25.0% -6.3% -66.7% IDXX
Better return on capitalReturn on invested capital 45.6% -0.2% — IDXX
Less leveragedLower net debt / EBITDA 0.5x 5.4x — IDXX
Higher dividend yieldTrailing dividend yield 0.00% 0.00% 0.00% –
Better 1-year returnPrice return, last 12 months -11.3% +96.8% +253.8% BFLY
Better 5-year returnAnnualised price return, 5 years -3.3%/yr -22.1%/yr -5.4%/yr IDXX
Less volatileAnnualised volatility, 1 year 32.0% 55.7% 115.0% IDXX
Higher overall scoreMean of the five percentile scores vs peers 78/100 57/100 45/100 IDXX

Percentile Scorecard

IDXXNEOGBFLY

Each axis is the mean percentile of its metrics against the company's industry group. 100 is the best in the group, 50 the middle.

Scores by Axis

AxisIDXXNEOGBFLY
Valuation 75 #155 of 625 73 #63 of 227 29 #161 of 227
Growth 76 #147 of 602 50 #111 of 219 67 #72 of 219
Profitability 97 #18 of 549 63 #76 of 205 33 #138 of 205
Financial Health 46 #351 of 654 46 #128 of 237 61 #92 of 237
Shareholder Returns 93 #26 of 367 55 #61 of 135 37 #86 of 135
Overall 78 57 45
  • IDXX ranked among 672 companies in Pharmaceuticals and Biotechnology
  • NEOG ranked among 247 companies in Medical Devices and Diagnostics
  • BFLY ranked among 247 companies in Medical Devices and Diagnostics

Price Performance

Price return, split-adjusted, before dividends. Click a name to hide or show it.

Returns

PeriodIDXXNEOGBFLYSPY
1 month +6.4%-11.7%-14.5% +0.9%
3 months -1.2%+28.9%+10.3% +5.9%
6 months +1.7%+34.5%+58.9% +8.5%
Year to date -16.8%+73.4%+105.8% +13.3%
1 year -11.3%+96.8%+253.8% +12.4%
3 years +43.8%-20.9%+889.9% +88.1%
3 years, per year +12.9%-7.5%+114.8% +23.5%
5 years -15.5%-71.4%-24.2% +68.2%
5 years, per year -3.3%-22.1%-5.4% +11.0%
10 years +435.8%-38.0%— +263.4%
10 years, per year +18.3%-4.7%— +13.8%

Risk

MeasureIDXXNEOGBFLYSPY
Volatility, 1Y 32.0%55.7%115.0% 12.7%
Downside volatility, 1Y 31.2%46.7%91.7% 12.7%
Beta vs S&P 500, 1Y 0.801.443.01 1.00
Return / volatility, 1Y -0.351.742.21 0.98
Max drawdown, 5Y -51.3%-90.6%-93.4% -25.4%
From 52-week high -26.6%-13.3%-21.3% -0.9%
52-week high $766.68$13.98$9.94 $779.14
52-week low $504.70$5.41$1.97 $631.97

Valuation History

Weekly multiples on trailing twelve-month fundamentals. Negative or extreme readings (a loss year, a collapsed denominator) are left out so the chart stays readable.

MultipleIDXXNEOGBFLY
P/E now vs peer median 39.0xmedian 17.4x -47.1xmedian 28.8x -27.4xmedian 28.8x
P/S now vs peer median 9.8xmedian 9.1x 3.0xmedian 3.0x 16.6xmedian 3.0x
EV/EBITDA now vs peer median 28.0xmedian 17.1x 29.3xmedian 17.4x -24.0xmedian 17.4x
P/FCF now vs peer median 35.4xmedian 19.0x 53.1xmedian 25.7x -66.4xmedian 25.7x
P/B now vs peer median 27.5xmedian 2.2x 1.3xmedian 2.4x 9.8xmedian 2.4x
PEG now vs peer median 2.58median 0.34 1.68median 1.03 -1.01median 1.03

Financial History

Reported figures by fiscal period, placed on the calendar year (or quarter) each period ended in, so companies with different fiscal years line up.

Trailing twelve monthsIDXXNEOGBFLY
Revenue $4.55B $883.99M $112.15M
Gross profit $2.84B $418.98M $59.04M
Operating income $1.46B -$7.38M -$79.38M
Net income $1.14B -$56.10M -$74.85M
Free cash flow $1.25B $49.80M -$28.04M
R&D $261.47M $19.76M $38.10M
EPS (diluted) $14.37 $-0.26 $-0.29
Cash & equivalents $196.93M $172.00M $124.66M
Total debt $968.86M $774.20M –
Shares (diluted) 79.31M 218.10M 262.10M
Enterprise value $44.61B $2.01B $1.39B

All Metrics

58 metrics · best in bold

Bold marks the best reading: the lowest positive value for multiples, leverage and payout, the highest for everything else. The bar under each value is its percentile against that company's own peers. Hover a value for its rank and the peer median.

Valuation

12 metrics
MetricIDXXNEOGBFLY
P/E 39.0x -47.1x -27.4x
P/FCF 35.4x 53.1x -66.4x
P/Operating cash flow 32.4x 31.0x -77.5x
P/S 9.8x 3.0x 16.6x
P/B 27.5x 1.3x 9.8x
P/Tangible book 29.3x 3.3x 10.2x
EV/EBITDA 28.0x 29.3x -24.0x
EV/EBIT 31.0x -440.3x -21.9x
EV/Revenue 9.9x 3.7x 15.5x
EV/FCF 36.0x 65.2x -61.9x
EV/Operating cash flow 32.9x 38.1x -72.3x
PEG (3Y EPS CAGR) 2.58 1.68 -1.01

Growth

14 metrics
MetricIDXXNEOGBFLY
Revenue growth (1Y) 12.8% -0.3% 28.1%
Revenue CAGR (3Y) 9.0% -1.3% 15.6%
Gross profit growth (1Y) 14.4% 1.8% 8.8%
Gross profit CAGR (3Y) 10.5% -3.1% 13.3%
Operating income growth (1Y) 16.2% 99.3% -14.8%
Operating income CAGR (3Y) 11.7% -29.0% 21.1%
Net income growth (1Y) 15.6% 94.6% -19.1%
Net income CAGR (3Y) 12.9% -28.3% 20.8%
EPS growth (1Y) 18.1% 94.6% -12.9%
EPS CAGR (3Y) 15.1% -28.0% 27.0%
Operating cash flow growth (1Y) 51.4% -1.9% 19.6%
Operating cash flow CAGR (3Y) 22.5% 2.9% 44.5%
Free cash flow growth (1Y) 59.9% 1,631% 12.2%
Free cash flow CAGR (3Y) 28.4% 126.1% 42.8%

Profitability

14 metrics
MetricIDXXNEOGBFLY
Gross margin 62.4% 47.4% 52.6%
EBITDA margin 35.4% 12.5% -64.4%
Operating margin 32.0% -0.8% -70.8%
Pretax margin 31.3% -7.7% -66.7%
Net margin 25.0% -6.3% -66.7%
FCF margin 27.5% 5.6% -25.0%
Operating cash flow margin 30.1% 9.6% -21.4%
Return on equity 71.9% -2.7% -39.3%
Return on assets 33.4% -1.7% -26.3%
Return on invested capital 45.6% -0.2% –
Return on capital employed 68.6% -0.2% -35.1%
Asset turnover 1.3x 0.3x 0.4x
Cash conversion (OCF / net income) 1.2x -1.5x 0.3x
Stock comp / revenue 1.4% 1.3% 21.3%

Financial Health

11 metrics
MetricIDXXNEOGBFLY
Debt / assets 28.1% 23.4% –
Debt / equity 0.6x 0.4x –
Net debt / EBITDA 0.5x 5.4x –
Debt / FCF 0.8x 15.5x –
Liabilities / assets 53.2% 36.8% 33.1%
Equity / assets 46.8% 63.2% 66.9%
Interest coverage 38.6x – -59.4x
Current ratio 1.2x 3.9x 4.1x
Quick ratio 0.7x 2.1x 2.7x
Cash ratio 0.2x 1.2x 2.1x
Altman Z-score 20.21 1.49 7.69

Shareholder Returns

7 metrics
MetricIDXXNEOGBFLY
Dividend yield – – –
Net buyback yield 2.4% -0.1% -0.4%
Shareholder yield 2.4% -0.1% -0.4%
Payout ratio (earnings) – – –
Payout ratio (FCF) – – –
Dividend growth (1Y) – – –
Dividend CAGR (3Y) – – –

Analyst Estimates

Solid lines are reported fiscal-year results; dashed lines are the consensus for the years ahead. Hover a year for the analysts' high and low, and how each result compared with its estimate.

ConsensusIDXXNEOGBFLY
Forward P/E 36.0xFY2026 37.9xFY2026 –
EPS, next fiscal year $15.63FY2026 $0.32FY2026 $-0.10FY2026
EPS growth, next FY +19.5%FY2026 0.0%FY2026 –
EPS growth, the year after +12.9% +31.3% –
Revenue, next fiscal year $5.00BFY2026 $847.28MFY2026 $114.50MFY2026
Revenue growth, next FY +16.3%FY2026 -2.7%FY2026 +17.3%FY2026
Revenue growth, the year after +0.6% -1.5% +26.0%

Institutional Ownership

13F filings, quarter ended Jun 30, 2026
HoldersIDXXNEOGBFLY
Held by institutions 93.6% 100.0% 59.9%
Institutions holding 1,289 315 245
Change in shares held, QoQ +4.1% +1.6% +13.9%
Institutions buying 587 151 143
Institutions selling 496 106 59
Buyers to sellers 1.18 1.42 2.42

Return Correlation

Daily returns, last 12 months

1.00 means two stocks move in lockstep, 0 that they move independently. Pairs below about 0.5 diversify each other.

IDXXNEOGBFLY
IDXX 1.00 0.24 0.28
NEOG 0.24 1.00 0.25
BFLY 0.28 0.25 1.00

Add a Peer

Largest companies in the same industry

Related Comparisons

Frequently Asked Questions

Which is bigger, IDXX, NEOG and BFLY?

Idexx Laboratories (IDXX) is the largest by market capitalisation: Idexx Laboratories (IDXX) $45.40B, Neogen (NEOG) $2.68B, Butterfly Network (BFLY) $1.94B.

Which company is growing faster?

Butterfly Network (BFLY) grew revenue fastest over the trailing twelve months: Idexx Laboratories (IDXX) +12.8%, Neogen (NEOG) -0.3%, Butterfly Network (BFLY) +28.1%.

Which company is more profitable?

Idexx Laboratories (IDXX) has the highest net margin (Idexx Laboratories (IDXX) 25.0%, Neogen (NEOG) -6.3%, Butterfly Network (BFLY) -66.7%). On return on invested capital, Idexx Laboratories (IDXX) leads (Idexx Laboratories (IDXX) 45.6%, Neogen (NEOG) -0.2%).

Which stock has performed better?

Over the past year Butterfly Network (BFLY) returned the most: Idexx Laboratories (IDXX) -11.3%, Neogen (NEOG) +96.8%, Butterfly Network (BFLY) +253.8%. Over five years, Idexx Laboratories (IDXX) compounded fastest (Idexx Laboratories (IDXX) -3.3%/yr, Neogen (NEOG) -22.1%/yr, Butterfly Network (BFLY) -5.4%/yr). Returns are price only, before dividends.

Which stock is riskier?

By one-year price volatility, Idexx Laboratories (IDXX) has been the steadiest (Idexx Laboratories (IDXX) 32.0%, Neogen (NEOG) 55.7%, Butterfly Network (BFLY) 115.0%). Volatility measures how widely the price swings, not the risk of the business.

Which is the better stock, IDXX, NEOG and BFLY?

There is no single answer; it depends on what you are buying for. On the 12 head-to-head measures on this page, Idexx Laboratories (IDXX) leads on 8. Business Quant does not give investment advice; use the comparison as a starting point for your own research.

Data from SEC filings, exchange prices and consensus estimates, via Business Quant. Percentile scores compare each company with its own peer group, so two companies' scores are each relative to different peers unless you rank against the whole market. Price returns exclude dividends. Nothing on this page is investment advice.